Defining exacerbations in chronic obstructive pulmonary disease

References

• Chronic_Respiratory_Diseases. Available from: www.who.int/gard/publications/chronic_respiratory_diseases.pdf [Last accessed 24 July 2014]
   Google Scholar
• Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998;158:49-59
   PubMed Web of Science ®Google Scholar
• Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-73
   PubMed Web of Science ®Google Scholar
• Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-50
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22
   PubMed Web of Science ®Google Scholar
• Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003;58:752-6
   PubMed Web of Science ®Google Scholar
• Global Strategy for Diagnosis, Management, and Prevention of COPD. 2014. Available from: www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf [Last accessed 14 February 2014]
   Google Scholar
• Donaldson GC, Wedzicha JA. COPD exacerbations. 1: Epidemiology. Thorax 2006;61:164-8
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38
   PubMed Web of Science ®Google Scholar
• Suzuki M, Makita H, Ito YM, et al. Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur Respir J 2014;43:1289-97
   PubMed Web of Science ®Google Scholar
• Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006;61:250-8
   PubMed Web of Science ®Google Scholar
• Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-23
   PubMed Web of Science ®Google Scholar
• Sunyer J, Sáez M, Murillo C, et al. Air pollution and emergency room admissions for chronic obstructive pulmonary disease: a 5-year study. Am J Epidemiol 1993;137:701-5
   PubMed Web of Science ®Google Scholar
• Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71-8
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:1298-303
   PubMed Web of Science ®Google Scholar
• Walters JA, Tan DJ, White CJ, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;9:Cd001288
   Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012;186:48-55
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007;14(Suppl B)):5b-32b
   Google Scholar
• Nagai A. [Guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 3rd edition]. Nihon Rinsho 2011;69:1729-34
   PubMedGoogle Scholar
• De Coster DA, Jones M. Tailoring of corticosteroids in COPD management. Curr Respir Care Rep 2014;3:121-32
   PubMedGoogle Scholar
• Miravitlles M, Soler-Cataluna JJ, Calle M, et al. A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Prim Care Respir J 2013;22:117-21
   PubMedGoogle Scholar
• Miravitlles M, Soler-Cataluna JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013;41:1252-6
   PubMed Web of Science ®Google Scholar
• Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005;60:480-7
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Pride NB, et al. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. Eur Respir J 1992;5:1254-61
   PubMedGoogle Scholar
• Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117:5s-9s
   PubMed Web of Science ®Google Scholar
• Effing TW, Kerstjens HA, Monninkhof EM, et al. Definitions of exacerbations: does it really matter in clinical trials on COPD? Chest 2009;136:918-23
   PubMed Web of Science ®Google Scholar
• Aaron SD, Fergusson D, Marks GB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008;63:122-8
   PubMed Web of Science ®Google Scholar
• Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003;41:46s-53s
   PubMedGoogle Scholar
• Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Molken MP. Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? Eur Respir J 2010;35:79-87
   PubMed Web of Science ®Google Scholar
• Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880-7
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13
   PubMed Web of Science ®Google Scholar
• Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009
   Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209
   PubMed Web of Science ®Google Scholar
• Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011;183:323-9
   PubMed Web of Science ®Google Scholar
• Mackay AJ, Donaldson GC, Patel AR, et al. Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). Eur Respir J 2014;43:735-44
   PubMed Web of Science ®Google Scholar
• Mackay AJ, Donaldson GC, Patel AR, et al. Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med 2012;185:1218-24
   PubMed Web of Science ®Google Scholar
• Bischoff EW, Boer LM, Molema J, et al. Validity of an automated telephonic system to assess COPD exacerbation rates. Eur Respir J 2012;39:1090-6
   PubMedGoogle Scholar
• Bourne S, Cohet C, Kim V, et al. Acute Exacerbation and Respiratory InfectionS in COPD (AERIS): protocol for a prospective, observational cohort study. BMJ Open 2014;4:e004546
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax 2006;61:354-61
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115:949-52
   PubMed Web of Science ®Google Scholar
• Kelly E, Owen CA, Pinto-Plata V, Celli BR. The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. Expert Rev Respir Med 2013;7:57-64
   PubMed Web of Science ®Google Scholar
• Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-74
   PubMed Web of Science ®Google Scholar
• Koutsokera A, Kostikas K, Nicod LP, Fitting JW. Pulmonary biomarkers in COPD exacerbations: a systematic review. Respir Res 2013;14:111
   PubMed Web of Science ®Google Scholar
• Brindicci C, Ito K, Resta O, et al. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J 2005;26:52-9
   PubMed Web of Science ®Google Scholar
• Agusti AG, Villaverde JM, Togores B, Bosch M. Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999;14:523-8
   PubMed Web of Science ®Google Scholar
• Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-21
   PubMed Web of Science ®Google Scholar
• Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax 2009;64:424-9
   PubMed Web of Science ®Google Scholar
• Kersul AL, Iglesias A, Rios A, et al. Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2011;47:176-83
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Seemungal TA, Donaldson GC, Wedzicha JA. Effects of exacerbations and seasonality on exhaled nitric oxide in COPD. Eur Respir J 2005;26:1009-15
   PubMed Web of Science ®Google Scholar
• Antus B, Barta I, Horvath I, Csiszer E. Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology 2010;15:472-7
   PubMed Web of Science ®Google Scholar
• Antus B, Barta I, Kullmann T, et al. Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: A longitudinal study. Am J Respir Crit Care Med 2010;182:1492-7
   PubMed Web of Science ®Google Scholar
• Horvath I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005;26:523-48
   PubMed Web of Science ®Google Scholar
• Koutsokera A, Loukides S, Gourgoulianis KI, Kostikas K. Biomarkers in the exhaled breath condensate of healthy adults: mapping the path towards reference values. Curr Med Chem 2008;15:620-30
   PubMed Web of Science ®Google Scholar
• Tateosian NL, Costa MJ, Guerrieri D, et al. Inflammatory mediators in exhaled breath condensate of healthy donors and exacerbated COPD patients. Cytokine 2012;58:361-7
   PubMedGoogle Scholar
• Gessner C, Scheibe R, Wotzel M, et al. Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir Med 2005;99:1229-40
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Resta O, Foschino-Barbaro MP, et al. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol 2004;505:169-75
   PubMed Web of Science ®Google Scholar
• Ko FW, Leung TF, Wong GW, et al. Measurement of tumor necrosis factor-alpha, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2009;4:79-86
   PubMedGoogle Scholar
• Mazur W, Stark H, Sovijarvi A, et al. Comparison of 8-isoprostane and interleukin-8 in induced sputum and exhaled breath condensate from asymptomatic and symptomatic smokers. Respiration 2009;78:209-16
   PubMed Web of Science ®Google Scholar
• Sethi S, Muscarella K, Evans N, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000;118:1557-65
   PubMed Web of Science ®Google Scholar
• Sethi S, Wrona C, Eschberger K, et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:491-7
   PubMed Web of Science ®Google Scholar
• Parameswaran GI, Sethi S, Murphy TF. Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD. Chest 2011;140:611-17
   PubMed Web of Science ®Google Scholar
• Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007;29:527-34
   PubMed Web of Science ®Google Scholar
• Tsimogianni AM, Papiris SA, Kanavaki S, et al. Predictors of positive sputum cultures in exacerbations of chronic obstructive pulmonary disease. Respirology 2009;14:1114-20
   PubMedGoogle Scholar
• Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, et al. Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med 2009;103:601-6
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Kruesmann F, Haverstock D, et al. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Respir J 2012;39:1354-60
   PubMed Web of Science ®Google Scholar
• Zhu A, Ge D, Zhang J, et al. Sputum myeloperoxidase in chronic obstructive pulmonary disease. Eur J Med Res 2014;19:12
   PubMed Web of Science ®Google Scholar
• Drozdovszky O, Barta I, Antus B. Sputum eicosanoid profiling in exacerbations of chronic obstructive pulmonary disease. Respiration 2014;87:408-15
   PubMed Web of Science ®Google Scholar
• Bathoorn E, Liesker J, Postma D, et al. Safety of sputum induction during exacerbations of COPD. Chest 2007;131:432-8
   PubMed Web of Science ®Google Scholar
• Gao P, Gibson PG, Zhang J, et al. The safety of sputum induction in adults with acute exacerbation of COPD. Clin Respir J 2013;7:101-9
   PubMedGoogle Scholar
• Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Harper-Owen R, Bhowmik A, et al. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 2000;16:677-83
   PubMed Web of Science ®Google Scholar
• Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349-55
   PubMed Web of Science ®Google Scholar
• Qiu Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:968-75
   PubMed Web of Science ®Google Scholar
• Kelly E, Owen CA, Abraham A, et al. Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease. F1000Res 2013;2:114
   PubMedGoogle Scholar
• Koutsokera A, Stolz D, Loukides S, Kostikas K. Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. Chest 2012;141:396-405
   PubMed Web of Science ®Google Scholar
• Phua J, Koay ES, Zhang D, et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. Eur Respir J 2006;28:695-702
   PubMed Web of Science ®Google Scholar
• Bozinovski S, Hutchinson A, Thompson M, et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:269-78
   PubMed Web of Science ®Google Scholar
• Creutzberg EC, Wouters EF, Vanderhoven-Augustin IM, et al. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1239-45
   PubMed Web of Science ®Google Scholar
• Stolz D, Breidthardt T, Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008;133:1088-94
   PubMed Web of Science ®Google Scholar
• Daniels JM, Schoorl M, Snijders D, et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010;138:1108-15
   PubMed Web of Science ®Google Scholar
• Daubin C, Parienti JJ, Vabret A, et al. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study. BMC Infect Dis 2008;8:145
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Morgenthaler NG, et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008;134:263-72
   PubMed Web of Science ®Google Scholar
• Rohde G, Gevaert P, Holtappels G, et al. Soluble interleukin-5 receptor alpha is increased in acute exacerbation of chronic obstructive pulmonary disease. Int Arch Allergy Immunol 2004;135:54-61
   PubMedGoogle Scholar
• Quint JK, Donaldson GC, Goldring JJ, et al. Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest 2010;137:812-22
   PubMed Web of Science ®Google Scholar
• Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007;131:1058-67
   PubMed Web of Science ®Google Scholar
• Brekke PH, Omland T, Holmedal SH, et al. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J 2008;31:563-70
   PubMed Web of Science ®Google Scholar
• Holland M, Alkhalil M, Chandromouli S, et al. Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. Respirology 2010;15:165-7
   PubMed Web of Science ®Google Scholar
• Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150:1646-52
   PubMed Web of Science ®Google Scholar
• Peng C, Tian C, Zhang Y, et al. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci 2013;345:190-4
   PubMed Web of Science ®Google Scholar
• Dev D, Wallace E, Sankaran R, et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998;92:664-7
   PubMed Web of Science ®Google Scholar
• Clark TW, Medina MJ, Batham S, et al. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J 2014;45(1):76-86
   Google Scholar
• Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama 2013;309:2353-61
   PubMed Web of Science ®Google Scholar
• Bartziokas K, Papaioannou AI, Loukides S, et al. Serum uric acid as a predictor of mortality and future exacerbations of COPD. Eur Respir J 2014;43:43-53
   PubMed Web of Science ®Google Scholar
• Minas M, Mystridou P, Georgoulias P, et al. Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD. COPD 2013;10:28-34
   PubMedGoogle Scholar
• Nikolakopoulou S, Hillas G, Perrea D, et al. Serum angiopoietin-2 and CRP levels during COPD exacerbations. COPD 2014;11:46-51
   PubMedGoogle Scholar